Chronic Inducible Urticaria Epidemiology Forecast

DelveInsight’s ‘Chronic Inducible Urticaria – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted chronic inducible urticaria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Chronic Inducible Urticaria: Understanding

The DelveInsight’s chronic inducible urticaria (CIndU) epidemiology report gives a thorough understanding of the CIndU by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for CIndU in the US, Europe, and Japan. Moreover, the report covers the detailed information of the chronic inducible urticaria epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight

This section encompassing chronic inducible urticaria (CIndU) epidemiology provides insights about historical and current patient pool and forecasted trend for every seven major countries. The CIndU epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Detailed Epidemiology Segmentation

The chronic inducible urticaria epidemiology covered in the report provides historical as well as forecasted CIndU epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.


The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The chronic inducible urticaria (CIndU) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The CIndU report and model provide an overview of the global trends of CIndU in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of CIndU in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of chronic inducible urticaria.
  • The report provides the segmentation of the Chronic Inducible Urticaria epidemiology

Report Highlights

  • 11-year Forecast of Chronic Inducible Urticaria Epidemiology
  • 7MM Coverage
  • Diagnosed prevalent cases of CU
  • Diagnosed prevalent cases of CIndU
  • Prevalence of chronic inducible urticaria by types

KOL – Views:

We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to chronic inducible urticaria (CIndU)?
  • What are the key findings pertaining to the chronic inducible urticaria (CIndU) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
  • What would be the total number of patients of chronic inducible urticaria (CIndU) across the 7MM during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
  • What is the disease risk, burden and unmet needs of chronic inducible urticaria (CIndU)?
  • What are the currently available treatments of chronic inducible urticaria (CIndU)?

Reasons to buy

The chronic inducible urticaria (CIndU) Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global chronic inducible urticaria (CIndU) market.
  • Quantify patient populations in the global chronic inducible urticaria (CIndU) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic inducible urticaria (CIndU) therapeutics in each of the markets covered
  • Understand the magnitude of chronic inducible urticaria (CIndU) population by its epidemiology
  • The chronic inducible urticaria (CIndU) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1 Key Insights

2 Executive Summary of Chronic Inducible Urticaria

3 SWOT Analysis for Chronic Inducible Urticaria

4 Chronic Inducible Urticaria Epidemiology Overview at a Glance

4.1 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2017

4.2 Patient Share (%) Distribution of Chronic Inducible Urticaria in 2030

5 Chronic Inducible Urticaria Market Overview at a Glance

5.1 Market Share (%) Distribution of Chronic Inducible Urticaria in 2017

5.2 Market Share (%) Distribution of Chronic Inducible Urticaria in 2030

6 Disease Background and Overview

6.1 Introduction

6.2 Types

6.3 Pathophysiology

6.4 Clinical features

6.5 Diagnosis

6.6 Clinical manifestation

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Total Prevalent Population of CIndU in 7MM

7.3 Assumptions and Rationale: 7MM

8 Country-wise Epidemiology of Chronic Inducible Urticaria

8.1 The United States

8.1.1 Diagnosed Prevalent cases of CU in the United States

8.1.2 Diagnosed Prevalent cases of CIndU in the United States

8.1.3 Prevalence of Chronic Inducible Urticaria by Types in the United States

8.2 EU5

8.2.1 Germany

8.2.2 France

8.2.3 Italy

8.2.4 Spain

8.2.5 The United Kingdom

8.3 Japan

8.3.1 Diagnosed Prevalent cases of CU in Japan

8.3.2 Diagnosed Prevalent cases of CIndU in Japan

8.3.3 Prevalence of Chronic Inducible Urticaria by Types in Japan

9 Treatment and Management

9.1 Guidelines

10 Case Study

10.1 Severe cold urticaria including anaphylaxis

10.2 Severe symptomatic dermographism (urticaria factitia)

11 Patient Journey

12 Unmet Needs

13 Appendix

13.1 Report Methodology

14 DelveInsight Capabilities

15 Disclaimer

16 About DelveInsight

List of Tables

Table 1: Summary of CIndU Market, Epidemiology, and Key Events (2017–2030)

Table 2: Total cases of Chronic Inducible Urticaria in 7MM (2017–2030)

Table 3: Diagnosed Prevalent cases of CU in the United States (2017–2030)

Table 4: Diagnosed Prevalent cases of CIndU in the United States (2017–2030)

Table 5: Prevalence of Chronic Inducible Urticaria by Types in the United States (2017–2030)

Table 6: Diagnosed Prevalent cases of CU in Germany (2017–2030)

Table 7: Diagnosed Prevalent cases of CIndU in Germany (2017–2030)

Table 8: Prevalence of Chronic Inducible Urticaria by Types in Germany (2017–2030)

Table 9: Diagnosed Prevalent cases of CU in France (2017–2030)

Table 10: Diagnosed Prevalent cases of CIndU in France (2017–2030)

Table 11: Prevalence of Chronic Inducible Urticaria by Types in France (2017–2030)

Table 12: Diagnosed Prevalent cases of CU in Italy (2017–2030)

Table 13: Diagnosed Prevalent cases of CIndU in Italy (2017–2030)

Table 14: Prevalence of Chronic Inducible Urticaria by Types in Italy (2017–2030)

Table 15: Diagnosed Prevalent cases of CU in Spain (2017–2030)

Table 16: Diagnosed Prevalent cases of CIndU in Spain (2017–2030)

Table 17: Prevalence of Chronic Inducible Urticaria by Types in Spain (2017–2030)

Table 18: Diagnosed Prevalent cases of CU in the United Kingdom (2017–2030)

Table 19: Diagnosed Prevalent cases of CIndU in the United Kingdom (2017–2030)

Table 20: Prevalence of Chronic Inducible Urticaria by Types in the United Kingdom (2017–2030)

Table 21: Diagnosed Prevalent cases of CU in Japan (2017–2030)

Table 22: Diagnosed Prevalent cases of CIndU in Japan (2017–2030)

Table 23: Prevalence of Chronic Inducible Urticaria by Types in Japan (2017–2030)

List of Figures

Figure 1: SWOT Analysis

Figure 2: The Inflammation of Mast Cells in Chronic Inducible Urticaria

Figure 3: The Inflammation of Mast Cells in Chronic Inducible Urticaria

Figure 4: Recommended diagnostic algorithm for chronic urticaria

Figure 5: Total cases of Chronic Inducible Urticaria in 7MM (2017–2030)

Figure 6: Diagnosed Prevalent cases of CU in the United States (2017–2030)

Figure 7: Diagnosed Prevalent cases of CIndU in the United States (2017–2030)

Figure 8: Prevalence of Chronic Inducible Urticaria by Types in the United States(2017–2030)

Figure 9: Diagnosed Prevalent cases of CU in Germany (2017–2030)

Figure 10: Diagnosed Prevalent cases of CIndU in Germany (2017–2030)

Figure 11: Prevalence of Chronic Inducible Urticaria by Types in Germany(2017–2030)

Figure 12: Diagnosed Prevalent cases of CU in France (2017–2030)

Figure 13: Diagnosed Prevalent cases of CIndU in France (2017–2030)

Figure 14: Prevalence of Chronic Inducible Urticaria by Types in France(2017–2030)

Figure 15: Diagnosed Prevalent cases of CU in Italy (2017–2030)

Figure 16: Diagnosed Prevalent cases of CIndU in Italy (2017–2030)

Figure 17: Prevalence of Chronic Inducible Urticaria by Types in Italy(2017–2030)

Figure 18: Diagnosed Prevalent cases of CU in Spain (2017–2030)

Figure 19: Diagnosed Prevalent cases of CIndU in Spain (2017–2030)

Figure 20: Prevalence of Chronic Inducible Urticaria by Types in Spain(2017–2030)

Figure 21: Diagnosed Prevalent cases of CU in the United Kingdom (2017–2030)

Figure 22: Diagnosed Prevalent cases of CIndU in the United Kingdom (2017–2030)

Figure 23: Prevalence of Chronic Inducible Urticaria by Types in the United Kingdom(2017–2030)

Figure 24: Diagnosed Prevalent cases of CU in Japan (2017–2030)

Figure 25: Diagnosed Prevalent cases of CIndU in Japan (2017–2030)

Figure 26: Prevalence of Chronic Inducible Urticaria by Types in Japan(2017–2030)

Figure 27: Recommended treatment algorithm for Chronic Urticaria

Figure 28: Patient Journey Chronic Inducible Urticaria

Figure 29: Unmet Needs

Figure 30: Market Drivers

Figure 31: Market Barriers

  • Tags:
  • Chronic Inducible Urticaria Epidemi...
  • Chronic Inducible Urticaria
  • Chronic Inducible Urticaria Pipeli...
  • Chronic Inducible Urticaria Compan...
  • Chronic Inducible Urticaria preval...
  • Chronic Inducible Urticaria incide...
  • Chronic Inducible Urticaria patien...
  • Chronic Inducible Urticaria treatm...

Forward to Friend

Need A Quote